|
Market Closed -
Other stock markets
|
After hours 05:27:38 am | |||
| 48.15 USD | +2.47% |
|
48.22 | +0.15% |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark | CI |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark | CI |
Evolution of the Average Target: CRISPR Therapeutics AG
Evolution of the Target Price: CRISPR Therapeutics AG
Changes in Analyst Recommendations: CRISPR Therapeutics AG
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +83.47% | |||||
| +18.45% | |||||
| +11.17% | |||||
| +33.57% | |||||
| +13.78% | |||||
| +48.7% | |||||
| +19.98% | |||||
| -10.53% | |||||
| +1.11% | |||||
| +9.41% | |||||
| Average | +22.91% | |||||
| Weighted average by Cap. | +20.17% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BofA Securities | |
| Chardan Research | |
| RBC Capital Markets | |
| Wedbush | |
| JPMorgan Chase | |
| Truist Securities | |
| Mizuho Securities | |
| TD Cowen | |
| HC Wainwright | |
| Oppenheimer | |
| Barclays | |
| Needham & Co. | |
| Baird | |
| Citigroup | |
| Morgan Stanley | |
| Wells Fargo Securities | |
| Wolfe Research | |
| Kempen | |
| JMP Securities | |
| Credit Suisse | |
| William Blair & Co. | |
| Stifel Nicolaus | |
| Cantor Fitzgerald | |
| Piper Sandler | |
| Bernstein | |
| EF Hutton | |
| SVB Securities LLC | |
| Goldman Sachs | |
| Evercore ISI | |
| BMO Capital | |
| SVB Leerink | |
| Brookline Capital Markets | |
| Cowen | |
| SMBC Nikko | |
| Canaccord Genuity | |
| Chardan | |
| Jefferies & Co. |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRSP Stock
- Consensus CRISPR Therapeutics AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition